148 related articles for article (PubMed ID: 19740630)
1. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan.
Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L
Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630
[TBL] [Abstract][Full Text] [Related]
2. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.
Rizos EN; Chatziioannou S; Siafakas N; Douzenis A; Katsantoni E; Mandrapilia A; Bacalis S; Fotiadis C; Lykouras L
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1135-6. PubMed ID: 20460141
[No Abstract] [Full Text] [Related]
3. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine.
Vesely C; Küfferle B; Brücke T; Kasper S
Int Clin Psychopharmacol; 2000 Jan; 15(1):57-60. PubMed ID: 10836289
[TBL] [Abstract][Full Text] [Related]
4. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.
Yoder KK; Hutchins GD; Morris ED; Brashear A; Wang C; Shekhar A
Schizophr Res; 2004 Dec; 71(2-3):371-5. PubMed ID: 15474908
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia.
Alptekin K; Kivircik BB
Int Clin Psychopharmacol; 2002 Sep; 17(5):263-4. PubMed ID: 12177588
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
Bressan RA; Jones HM; Pilowsky LS
J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
[TBL] [Abstract][Full Text] [Related]
7. Tardive dyskinesia in a patient treated with quetiapine.
Rizos E; Douzenis A; Gournellis R; Christodoulou C; Lykouras LP
World J Biol Psychiatry; 2009; 10(1):54-7. PubMed ID: 19673087
[TBL] [Abstract][Full Text] [Related]
8. Tardive dyskinesia related to quetiapine and confirmed by a DAT scan.
Chatziioannou SN; Rizos EN; Kallergi M; Douzenis A; Apostolopoulos A; Bacalis S; Lykouras L
J Clin Psychopharmacol; 2011 Aug; 31(4):535-8. PubMed ID: 21720231
[No Abstract] [Full Text] [Related]
9. Tardive dyskinesia with quetiapine.
Ghelber D; Belmaker RH
Am J Psychiatry; 1999 May; 156(5):796-7. PubMed ID: 10327920
[No Abstract] [Full Text] [Related]
10. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients.
Mané A; Gallego J; Lomeña F; Mateos JJ; Fernandez-Egea E; Horga G; Cot A; Pavia J; Bernardo M; Parellada E
Psychiatry Res; 2011 Oct; 194(1):79-84. PubMed ID: 21831607
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone.
Nelson MW; Reynolds RR; Kelly DL; Conley RR
Clin Neuropharmacol; 2003; 26(6):297-8. PubMed ID: 14646608
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study.
Lavalaye J; Sarlet A; Booij J; Linszen DH; Reneman L; Gersons BP; van Royen EA
Psychopharmacology (Berl); 2001 Apr; 155(1):107-9. PubMed ID: 11374328
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of dopamine receptor occupancy by [123I]IBZM-SPECT in schizophrenic patients treated with quetiapine.
Pávics L; Szekeres G; Ambrus E; Kéri S; Kovács Z; Argyelán M; Kanyó B; Csernay L; Janka Z
Nucl Med Rev Cent East Eur; 2004; 7(2):129-33. PubMed ID: 15968599
[TBL] [Abstract][Full Text] [Related]
14. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.
Costa A; Riedel M; Müller U; Möller HJ; Ettinger U
Synapse; 2011 Oct; 65(10):998-1005. PubMed ID: 21404331
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter availability in drug-naïve patients with schizophrenia and later psychotic symptoms severity.
Tseng HH; Chen KC; Chen PS; Lee IH; Chang WH; Yao WJ; Chiu NT; Yang YK
Schizophr Res; 2017 Dec; 190():185-186. PubMed ID: 28364963
[No Abstract] [Full Text] [Related]
16. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
17. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.
Tauscher J; Küfferle B; Asenbaum S; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Sep; 133(1):102-5. PubMed ID: 9335088
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.
Schmitt GJ; Frodl T; Dresel S; la Fougère C; Bottlender R; Koutsouleris N; Hahn K; Möller HJ; Meisenzahl EM
Eur Arch Psychiatry Clin Neurosci; 2006 Mar; 256(2):115-21. PubMed ID: 16284713
[TBL] [Abstract][Full Text] [Related]
19. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
Peritogiannis V; Tsouli S
J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment in schizophrenia is associated with prefrontal-striatal functional hypoconnectivity and striatal dopaminergic abnormalities.
Yang KC; Yang BH; Liu MN; Liou YJ; Chou YH
J Psychopharmacol; 2024 Jun; 38(6):515-525. PubMed ID: 38853592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
